Literature DB >> 10606723

Effective expression and purification of recombinant onconase, an antitumor protein.

E Notomista1, V Cafaro, R Fusiello, A Bracale, G D'Alessio, A Di Donato.   

Abstract

Several members of the RNase A superfamily are endowed with antitumor activity, showing selective cytotoxicity toward several tumor cell lines. One of these is onconase, the smallest member of the RNase A superfamily, which is at present undergoing phase III clinical trials. We report here the expression of recombinant onconase in Escherichia coli inclusion bodies, the correct processing of the protein, followed by its purification in high yields. The recombinant protein has biological and catalytic properties identical to those of the natural enzyme.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10606723     DOI: 10.1016/s0014-5793(99)01623-3

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  13 in total

1.  Oxidative folding and N-terminal cyclization of onconase.

Authors:  Ervin Welker; Laura Hathaway; Guoqiang Xu; Mahesh Narayan; Lovy Pradeep; Hang-Cheol Shin; Harold A Scheraga
Journal:  Biochemistry       Date:  2007-04-18       Impact factor: 3.162

Review 2.  The growing impact of lyophilized cell-free protein expression systems.

Authors:  J Porter Hunt; Seung Ook Yang; Kristen M Wilding; Bradley C Bundy
Journal:  Bioengineered       Date:  2016-10-28       Impact factor: 3.269

3.  Recombinant expression, different downstream processing of the disulfide-rich anti-tumor peptide Ranpirnase and its effect on the growth of human glioma cell line SHG-44.

Authors:  Xiao-Min Wang; Zhan-Yun Guo
Journal:  Biomed Rep       Date:  2013-07-17

Review 4.  Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes.

Authors:  W Ardelt; K Shogen; Z Darzynkiewicz
Journal:  Curr Pharm Biotechnol       Date:  2008-06       Impact factor: 2.837

Review 5.  Ribonucleases as potential modalities in anticancer therapy.

Authors:  Wojciech Ardelt; Barbara Ardelt; Zbigniew Darzynkiewicz
Journal:  Eur J Pharmacol       Date:  2009-10-14       Impact factor: 4.432

6.  Removal of N-terminal methionine from recombinant proteins by engineered E. coli methionine aminopeptidase.

Authors:  You-Di Liao; Jen-Chong Jeng; Chiu-Feng Wang; Sui-Chi Wang; Shu-Ting Chang
Journal:  Protein Sci       Date:  2004-07       Impact factor: 6.725

7.  Crystal structure of Onconase at 1.1 Å resolution--insights into substrate binding and collective motion.

Authors:  Daniel E Holloway; Umesh P Singh; Kuslima Shogen; K Ravi Acharya
Journal:  FEBS J       Date:  2011-09-28       Impact factor: 5.542

Review 8.  Leczyme: a new candidate drug for cancer therapy.

Authors:  Takeo Tatsuta; Shigeki Sugawara; Kohta Takahashi; Yukiko Ogawa; Masahiro Hosono; Kazuo Nitta
Journal:  Biomed Res Int       Date:  2014-04-23       Impact factor: 3.411

9.  Rational Design of a Carrier Protein for the Production of Recombinant Toxic Peptides in Escherichia coli.

Authors:  Katia Pane; Lorenzo Durante; Elio Pizzo; Mario Varcamonti; Anna Zanfardino; Valeria Sgambati; Antimo Di Maro; Andrea Carpentieri; Viviana Izzo; Alberto Di Donato; Valeria Cafaro; Eugenio Notomista
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

10.  Three-step procedure for preparation of pure Bacillus altitudinis ribonuclease.

Authors:  Elena Dudkina; Vera Ulyanova; Raihan Shah Mahmud; Vera Khodzhaeva; Linh Dao; Valentina Vershinina; Alexei Kolpakov; Olga Ilinskaya
Journal:  FEBS Open Bio       Date:  2016-01-19       Impact factor: 2.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.